|
Tanya Baker
Science and Technical Advisor, Medicines New Zealand Tanya Baker is the Science and Technical Advisor for Medicines New Zealand, the association representing the research-based pharmaceutical industry in Aotearoa New Zealand. Medicines New Zealand works with stakeholders in the health sector to encourage proactive conversations about improving access to modern medicines and vaccines, and is a key advocate for the benefits that clinical research by innovative biopharmaceutical companies bring to the New Zealand health system, economy and most critically patients in Aotearoa. Before joining Medicines New Zealand, Tanya worked in clinical research in NZ and the UK in roles in both the academic/non-commercial and pharmaceutical research sectors.
|
|
Commercial Clinical Research in Aotearoa - At a Crossroads?
The commercial clinical research sector is thriving in Aotearoa! Sponsors are interested in New Zealand, private sites are expanding with new locations giving more Kiwis the opportunity to participate in research, and experienced clinical research professionals are in hot demand. Commercial clinical research activity provides health and economic benefits to New Zealand and strengthens the viability of the overall health research sector in New Zealand.
With the Therapeutic Products Bill passing we are now 3 years away from moving into a new regulatory environment. The Enhancing Aotearoa New Zealand Clinical Trials project, funded by Manatū Hauora and the Health Research Council of New Zealand is also making progress. It is critical the new regulatory regime and emerging national clinical trials ecosystem enables New Zealand to remain an attractive destination for both commercial and non-commercial clinical research.
This talk “Commercial Clinical Research in Aotearoa - At a Crossroads?” aims to start a broader conversation across the research sector. It’s timely that we reflect upon current and past commercial research sector successes and identify future success factors for the new clinical trials environment to ensure that longer term the sector is sustainable and that New Zealand trials environment supports research and innovation.
With the Therapeutic Products Bill passing we are now 3 years away from moving into a new regulatory environment. The Enhancing Aotearoa New Zealand Clinical Trials project, funded by Manatū Hauora and the Health Research Council of New Zealand is also making progress. It is critical the new regulatory regime and emerging national clinical trials ecosystem enables New Zealand to remain an attractive destination for both commercial and non-commercial clinical research.
This talk “Commercial Clinical Research in Aotearoa - At a Crossroads?” aims to start a broader conversation across the research sector. It’s timely that we reflect upon current and past commercial research sector successes and identify future success factors for the new clinical trials environment to ensure that longer term the sector is sustainable and that New Zealand trials environment supports research and innovation.
